Jon-Kar Zubieta

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3237677/publications.pdf Version: 2024-02-01



ION-KAD ZURIETA

#	Article	IF	CITATIONS
1	Impaired frontostriatal functional connectivity among chronic opioid using pain patients is associated with dysregulated affect. Addiction Biology, 2020, 25, e12743.	2.6	17
2	Endogenous opioid system dysregulation in depression: implications for new therapeutic approaches. Molecular Psychiatry, 2019, 24, 576-587.	7.9	130
3	Multidimensional imaging techniques for prediction of treatment response in major depressive disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2019, 91, 38-48.	4.8	10
4	Impact of chronic migraine attacks and their severity on the endogenous μ-opioid neurotransmission in the limbic system. NeuroImage: Clinical, 2019, 23, 101905.	2.7	26
5	Mindfulness-Oriented Recovery Enhancement remediates hedonic dysregulation in opioid users: Neural and affective evidence of target engagement. Science Advances, 2019, 5, eaax1569.	10.3	77
6	Influence of childhood adversity, approach motivation traits, and depression on individual differences in brain activation during reward anticipation. Biological Psychology, 2019, 146, 107709.	2.2	16
7	Association between smoking, and hospital readmission among inpatients with psychiatric illness at an academic inpatient psychiatric facility, 2000–2015. Addictive Behaviors Reports, 2019, 9, 100181.	1.9	2
8	Cognitive Control as a 5-HT1A-Based Domain That Is Disrupted in Major Depressive Disorder. Frontiers in Psychology, 2019, 10, 691.	2.1	15
9	Neuropeptide Y and representation of salience in human nucleus accumbens. Neuropsychopharmacology, 2019, 44, 495-502.	5.4	10
10	Abnormal emotional and neural responses to romantic rejection and acceptance in depressed women. Journal of Affective Disorders, 2018, 234, 231-238.	4.1	13
11	Expectancy Modulation of Opioid Neurotransmission. International Review of Neurobiology, 2018, 138, 17-37.	2.0	21
12	Individuals with more severe depression fail to sustain nucleus accumbens activity to preferred music over time. Psychiatry Research - Neuroimaging, 2018, 275, 21-27.	1.8	22
13	Clinical Applications of Neuroimaging in Psychiatric Disorders. American Journal of Psychiatry, 2018, 175, 915-916.	7.2	37
14	Differential engagement of cognitive control regions and subgenual cingulate based upon presence or absence of comorbid anxiety with depression. Journal of Affective Disorders, 2018, 241, 371-380.	4.1	15
15	Reliability, Convergent Validity and Time Invariance of Default Mode Network Deviations in Early Adult Major Depressive Disorder. Frontiers in Psychiatry, 2018, 9, 244.	2.6	26
16	Reappraisal deficits promote craving and emotional distress among chronic pain patients at risk for prescription opioid misuse. Journal of Addictive Diseases, 2018, 37, 14-22.	1.3	13
17	Striatal dopaminergic reward response relates to age of first drunkenness and feedback response in atâ€risk youth. Addiction Biology, 2017, 22, 502-512.	2.6	17
18	Domainâ€specific impairment in cognitive control among remitted youth with a history of major depression. Microbial Biotechnology, 2017, 11, 383-392.	1.7	39

#	Article	IF	CITATIONS
19	Multidimensional prediction of treatment response to antidepressants with cognitive control and functional MRI. Brain, 2017, 140, 472-486.	7.6	61
20	An updated synthesis of [¹¹ C]carfentanil for positron emission tomography (PET) imaging of the μâ€opioid receptor. Journal of Labelled Compounds and Radiopharmaceuticals, 2017, 60, 375-380.	1.0	17
21	"Top-Down―Mu-Opioid System Function in Humans: Mu-Opioid Receptors in Ventrolateral Prefrontal Cortex Mediate the Relationship Between Hedonic Tone and Executive Function in Major Depressive Disorder. Journal of Neuropsychiatry and Clinical Neurosciences, 2017, 29, 357-364.	1.8	18
22	Meta-analysis of Neural Effects of Depression Therapies. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2017, 2, 305-306.	1.5	0
23	Restructuring Hedonic Dysregulation in Chronic Pain and Prescription Opioid Misuse: Effects of Mindfulness-Oriented Recovery Enhancement on Responsiveness to Drug Cues and Natural Rewards. Psychotherapy and Psychosomatics, 2017, 86, 111-112.	8.8	44
24	Striatal dopamine D2/3 receptor-mediated neurotransmission in major depression: Implications for anhedonia, anxiety and treatment response. European Neuropsychopharmacology, 2017, 27, 977-986.	0.7	70
25	817. Neuropeptide Y Genetic Risk Affects Striatal Response to Potential Loss. Biological Psychiatry, 2017, 81, S331-S332.	1.3	1
26	Metabolic and hormone influences on emotion processing during menopause. Psychoneuroendocrinology, 2017, 76, 218-225.	2.7	22
27	Differential Resting State Connectivity Patterns and Impaired Semantically Cued List Learning Test Performance in Early Course Remitted Major Depressive Disorder. Journal of the International Neuropsychological Society, 2016, 22, 225-239.	1.8	17
28	Nicotine-specific and non-specific effects of cigarette smoking on endogenous opioid mechanisms. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2016, 69, 69-77.	4.8	27
29	Pharmacological modulation of pulvinar resting-state regional oscillations and network dynamics in major depression. Psychiatry Research - Neuroimaging, 2016, 252, 10-18.	1.8	16
30	Oxytocin modulates hemodynamic responses to monetary incentives in humans. Psychopharmacology, 2016, 233, 3905-3919.	3.1	18
31	Acute cortisol reactivity attenuates engagement of fronto-parietal and striatal regions during emotion processing in negative mood disorders. Psychoneuroendocrinology, 2016, 73, 67-78.	2.7	22
32	Comorbid anxiety increases cognitive control activation in Major Depressive Disorder. Depression and Anxiety, 2016, 33, 967-977.	4.1	40
33	Constance E. Lieber, Theodore R. Stanley, and the Enduring Impact of Philanthropy on Psychiatry Research. Biological Psychiatry, 2016, 80, 84-86.	1.3	2
34	Decreased Fronto-Limbic Activation and Disrupted Semantic-Cued List Learning in Major Depressive Disorder. Journal of the International Neuropsychological Society, 2016, 22, 412-425.	1.8	13
35	Endogenous opioidergic dysregulation of pain in fibromyalgia: a PET and fMRI study. Pain, 2016, 157, 2217-2225.	4.2	130
36	Amygdala and dorsomedial hyperactivity to emotional faces in youth with remitted Major Depression. Social Cognitive and Affective Neuroscience, 2016, 11, 736-745.	3.0	15

#	Article	IF	CITATIONS
37	Salience Network Functional Connectivity Predicts Placebo Effects in Major Depression. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2016, 1, 68-76.	1.5	59
38	Mu Opioid Receptor Genetic Variation and Heroin Addiction. Biological Psychiatry, 2015, 78, 439-440.	1.3	2
39	Distinct cognitive effects of estrogen and progesterone in menopausal women. Psychoneuroendocrinology, 2015, 59, 25-36.	2.7	55
40	Chronic Back Pain Is Associated with Alterations in Dopamine Neurotransmission in the Ventral Striatum. Journal of Neuroscience, 2015, 35, 9957-9965.	3.6	137
41	Endogenous Opioid Mechanisms Are Implicated in Obesity and Weight Loss in Humans. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 3193-3201.	3.6	47
42	The double burden of age and major depressive disorder on the cognitive control network Psychology and Aging, 2015, 30, 475-485.	1.6	18
43	Brief Report: Excitatory and Inhibitory Brain Metabolites as Targets of Motor Cortex Transcranial Direct Current Stimulation Therapy and Predictors of Its Efficacy in Fibromyalgia. Arthritis and Rheumatology, 2015, 67, 576-581.	5.6	88
44	Stress Response to the Functional Magnetic Resonance Imaging Environment in Healthy Adults Relates to the Degree of Limbic Reactivity during Emotion Processing. Neuropsychobiology, 2015, 71, 85-96.	1.9	17
45	Shared dimensions of performance and activation dysfunction in cognitive control in females with mood disorders. Brain, 2015, 138, 1424-1434.	7.6	14
46	Association Between Placebo-Activated Neural Systems and Antidepressant Responses. JAMA Psychiatry, 2015, 72, 1087.	11.0	120
47	Affective personality predictors of disrupted reward learning and pursuit in major depressive disorder. Psychiatry Research, 2015, 230, 56-64.	3.3	17
48	Effects of the Mu Opioid Receptor Polymorphism (OPRM1 A118G) on Pain Regulation, Placebo Effects and Associated Personality Trait Measures. Neuropsychopharmacology, 2015, 40, 957-965.	5.4	125
49	Age and Gender Modulate the Neural Circuitry Supporting Facial Emotion Processing in Adults with Major Depressive Disorder. American Journal of Geriatric Psychiatry, 2015, 23, 304-313.	1.2	28
50	Dynamic Interactions Between Plasma IL-1 Family Cytokines and Central Endogenous Opioid Neurotransmitter Function in Humans. Neuropsychopharmacology, 2015, 40, 554-565.	5.4	23
51	Contributions of the paraventricular thalamic nucleus in the regulation of stress, motivation, and mood. Frontiers in Behavioral Neuroscience, 2014, 8, 73.	2.0	165
52	Indirect Effect of Corticotropin-Releasing Hormone Receptor 1 Gene Variation on Negative Emotionality and Alcohol Use via Right Ventrolateral Prefrontal Cortex. Journal of Neuroscience, 2014, 34, 4099-4107.	3.6	44
53	Differential prefrontal and subcortical circuitry engagement during encoding of semantically related words in patients with lateâ€ŀife depression. International Journal of Geriatric Psychiatry, 2014, 29, 1104-1115.	2.7	19
54	<i>μ</i> â€Opioid activation in the midbrain during migraine allodynia – brief report II. Annals of Clinical and Translational Neurology, 2014, 1, 445-450.	3.7	24

#	Article	IF	CITATIONS
55	<i>μ<</i> â€Opioid activation in the prefrontal cortex in migraine attacks – brief report I. Annals of Clinical and Translational Neurology, 2014, 1, 439-444.	3.7	34
56	The double burden of age and disease on cognition and quality of life in bipolar disorder. International Journal of Geriatric Psychiatry, 2014, 29, 952-961.	2.7	31
57	Reduced emotion processing efficiency in healthy males relative to females. Social Cognitive and Affective Neuroscience, 2014, 9, 316-325.	3.0	45
58	Development of Impulse Control Circuitry in Children of Alcoholics. Biological Psychiatry, 2014, 76, 708-716.	1.3	49
59	Valence-Specific Effects of <i>BDNF</i> Val ⁶⁶ Met Polymorphism on Dopaminergic Stress and Reward Processing in Humans. Journal of Neuroscience, 2014, 34, 5874-5881.	3.6	54
60	Effect of GABRA2 Genotype on Development of Incentive-Motivation Circuitry in a Sample Enriched for Alcoholism Risk. Neuropsychopharmacology, 2014, 39, 3077-3086.	5.4	47
61	Neurobiology of placebo effects: expectations or learning?. Social Cognitive and Affective Neuroscience, 2014, 9, 1013-1021.	3.0	45
62	Substance abuse risk in emerging adults associated with smaller frontal gray matter volumes and higher externalizing behaviors. Drug and Alcohol Dependence, 2014, 137, 68-75.	3.2	32
63	Relationship between impulsivity, prefrontal anticipatory activation, and striatal dopamine release during rewarded task performance. Psychiatry Research - Neuroimaging, 2014, 223, 244-252.	1.8	49
64	Left middle frontal gyrus response to inhibitory errors in children prospectively predicts early problem substance use. Drug and Alcohol Dependence, 2014, 141, 51-57.	3.2	77
65	Building up Analgesia in Humans via the Endogenous μ-Opioid System by Combining Placebo and Active tDCS: A Preliminary Report. PLoS ONE, 2014, 9, e102350.	2.5	71
66	Increased Coupling of Intrinsic Networks in Remitted Depressed Youth Predicts Rumination and Cognitive Control. PLoS ONE, 2014, 9, e104366.	2.5	91
67	Accumbens functional connectivity during reward mediates sensation-seeking and alcohol use in high-risk youth. Drug and Alcohol Dependence, 2013, 128, 130-139.	3.2	89
68	Personality Trait Predictors of Placebo Analgesia and Neurobiological Correlates. Neuropsychopharmacology, 2013, 38, 639-646.	5.4	160
69	Emotion regulation through execution, observation, and imagery of emotional movements. Brain and Cognition, 2013, 82, 219-227.	1.8	44
70	Personalized Medicine and Opioid Analgesic Prescribing for Chronic Pain: Opportunities and Challenges. Journal of Pain, 2013, 14, 103-113.	1.4	98
71	DRD2 polymorphisms modulate reward and emotion processing, dopamine neurotransmission and openness to experience. Cortex, 2013, 49, 877-890.	2.4	106
72	Alterations in Endogenous Opioid Functional Measures in Chronic Back Pain. Journal of Neuroscience, 2013, 33, 14729-14737.	3.6	57

#	Article	IF	CITATIONS
73	Hormonal Environment Affects Cognition Independent of Age during the Menopause Transition. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E1686-E1694.	3.6	72
74	Variation in the Corticotropin-Releasing Hormone Receptor 1 (<i>CRHR1</i>) Gene Influences fMRI Signal Responses during Emotional Stimulus Processing. Journal of Neuroscience, 2012, 32, 3253-3260.	3.6	55
75	Leptin Regulates Dopamine Responses to Sustained Stress in Humans. Journal of Neuroscience, 2012, 32, 15369-15376.	3.6	48
76	Nucleus Accumbens Response to Incentive Stimuli Anticipation in Children of Alcoholics: Relationships with Precursive Behavioral Risk and Lifetime Alcohol Use. Journal of Neuroscience, 2012, 32, 2544-2551.	3.6	102
77	Immediate Effects of tDCS on the μ-Opioid System of a Chronic Pain Patient. Frontiers in Psychiatry, 2012, 3, 93.	2.6	89
78	Resiliency in Adolescents at High Risk for Substance Abuse: Flexible Adaptation via Subthalamic Nucleus and Linkage to Drinking and Drug Use in Early Adulthood. Alcoholism: Clinical and Experimental Research, 2012, 36, 1355-1364.	2.4	33
79	Impact of chronic hypercortisolemia on affective processing. Neuropharmacology, 2012, 62, 217-225.	4.1	48
80	Tobacco smoking produces greater striatal dopamine release in G-allele carriers with mu opioid receptor A118G polymorphism. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2012, 38, 236-240.	4.8	38
81	Postmenopausal hormone use impact on emotion processing circuitry. Behavioural Brain Research, 2012, 226, 147-153.	2.2	24
82	Modality-specific alterations in the perception of emotional stimuli in Bipolar Disorder compared to Healthy Controls and Major Depressive Disorder. Cortex, 2012, 48, 1027-1034.	2.4	43
83	Oxytocin Gene Polymorphisms Influence Human Dopaminergic Function in a Sex-Dependent Manner. Biological Psychiatry, 2012, 72, 198-206.	1.3	87
84	Striatal Dopamine Release and Genetic Variation of the Serotonin 2C Receptor in Humans. Journal of Neuroscience, 2012, 32, 9344-9350.	3.6	41
85	μ-Opioid receptor availability in the amygdala is associated with smoking for negative affect relief. Psychopharmacology, 2012, 222, 701-708.	3.1	11
86	Sex differences in anterior cingulate cortex activation during impulse inhibition and behavioral correlates. Psychiatry Research - Neuroimaging, 2012, 201, 54-62.	1.8	65
87	Neural Correlates of Visual Motion Prediction. PLoS ONE, 2012, 7, e39854.	2.5	13
88	Association of Plasma Interleukin-18 Levels with Emotion Regulation and μ-Opioid Neurotransmitter Function in Major Depression and Healthy Volunteers. Biological Psychiatry, 2011, 69, 808-812.	1.3	71
89	Insulin resistance influences central opioid activity in polycystic ovary syndrome. Fertility and Sterility, 2011, 95, 2494-2498.	1.0	16
90	Insulin Resistance Influences Central Opioid Activity in Polycystic Ovary Syndrome. Obstetrical and Gynecological Survey, 2011, 66, 693-695.	0.4	0

#	Article	IF	CITATIONS
91	Realâ€time functional MRI using pseudoâ€continuous arterial spin labeling. Magnetic Resonance in Medicine, 2011, 65, 1570-1577.	3.0	11
92	Early Initiation of Hormone Therapy in Menopausal Women Is Associated with Increased Hippocampal and Posterior Cingulate Cholinergic Activity. Journal of Clinical Endocrinology and Metabolism, 2011, 96, E1761-E1770.	3.6	23
93	Human Mu Opioid Receptor (<i>OPRM1</i> A118G) polymorphism is associated with brain mu-opioid receptor binding potential in smokers. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 9268-9273.	7.1	130
94	Venous plasma nicotine correlates of hormonal effects of tobacco smoking. Pharmacology Biochemistry and Behavior, 2010, 95, 209-215.	2.9	34
95	fMRI BOLD responses to negative stimuli in the prefrontal cortex are dependent on levels of recent negative life stress in major depressive disorder. Psychiatry Research - Neuroimaging, 2010, 183, 202-208.	1.8	40
96	Dysregulation of Regional Endogenous Opioid Function in Borderline Personality Disorder. American Journal of Psychiatry, 2010, 167, 925-933.	7.2	129
97	Striatal Dysfunction Marks Preexisting Risk and Medial Prefrontal Dysfunction Is Related to Problem Drinking in Children of Alcoholics. Biological Psychiatry, 2010, 68, 287-295.	1.3	92
98	Short-term hormone treatment modulates emotion response circuitry in postmenopausal women. Fertility and Sterility, 2010, 93, 1929-1937.	1.0	17
99	Pain Signal as Threat and Reward. Neuron, 2010, 66, 6-7.	8.1	9
100	Tackling the Kraepelinian Dichotomy: A Neuroimaging Review. Psychiatric Annals, 2010, 40, 154-159.	0.1	2
101	Gender-specific disruptions in emotion processing in younger adults with depression. Depression and Anxiety, 2009, 26, 182-189.	4.1	52
102	Zhou et al. reply. Nature, 2009, 458, E7-E7.	27.8	1
103	Neurobiological Mechanisms of Placebo Responses. Annals of the New York Academy of Sciences, 2009, 1156, 198-210.	3.8	220
104	Practical Aspects of in Vivo Detection of Neuropeptides by Microdialysis Coupled Off-Line to Capillary LC with Multistage MS. Analytical Chemistry, 2009, 81, 2242-2250.	6.5	71
105	Enhanced neuroactivation during verbal memory processing in postmenopausal women receiving short-term hormone therapy. Fertility and Sterility, 2009, 92, 197-204.	1.0	32
106	In Memory of Elizabeth Young. Biological Psychiatry, 2009, 66, e25-e26.	1.3	1
107	Traditional Chinese acupuncture and placebo (sham) acupuncture are differentiated by their effects on μ-opioid receptors (MORs). NeuroImage, 2009, 47, 1077-1085.	4.2	265
108	The role of the endogenous opioid system in polycystic ovary syndrome. Fertility and Sterility, 2009, 92, 1-12.	1.0	63

#	Article	IF	CITATIONS
109	Genetic variation in human NPY expression affects stress response and emotion. Nature, 2008, 452, 997-1001.	27.8	387
110	Affective Circuitry and Risk for Alcoholism in Late Adolescence: Differences in Frontostriatal Responses Between Vulnerable and Resilient Children of Alcoholic Parents. Alcoholism: Clinical and Experimental Research, 2008, 32, 414-426.	2.4	87
111	It Is Time to Take a Stand for Medical Research and Against Terrorism Targeting Medical Scientists. Biological Psychiatry, 2008, 63, 725-727.	1.3	65
112	Monoamine Oxidase A Genotype Predicts Human Serotonin 1A Receptor Availability In Vivo. Journal of Neuroscience, 2008, 28, 11354-11359.	3.6	48
113	Decreased Central μ-Opioid Receptor Availability in Fibromyalgia. Journal of Neuroscience, 2007, 27, 10000-10006.	3.6	445
114	Smoking Modulation of μ-Opioid and Dopamine D2 Receptor-Mediated Neurotransmission in Humans. Neuropsychopharmacology, 2007, 32, 450-457.	5.4	115
115	Placebo effects on human μ-opioid activity during pain. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 11056-11061.	7.1	516
116	The sensitivity and psychometric properties of a brief computer-based cognitive screening battery in a depression clinic. Psychiatry Research, 2007, 152, 143-154.	3.3	43
117	Individual Differences in Reward Responding Explain Placebo-Induced Expectations and Effects. Neuron, 2007, 55, 325-336.	8.1	392
118	A task to manipulate attentional load, set-shifting, and inhibitory control: Convergent validity and test–retest reliability of the Parametric Go/No-Go Test. Journal of Clinical and Experimental Neuropsychology, 2007, 29, 842-853.	1.3	126
119	Buprenorphine Duration of Action: Mu-opioid Receptor Availability and Pharmacokinetic and Behavioral Indices. Biological Psychiatry, 2007, 61, 101-110.	1.3	102
120	Altered Central μ-Opioid Receptor Binding After Psychological Trauma. Biological Psychiatry, 2007, 61, 1030-1038.	1.3	109
121	Frontal and Limbic Activation During Inhibitory Control Predicts Treatment Response in Major Depressive Disorder. Biological Psychiatry, 2007, 62, 1272-1280.	1.3	186
122	Time-course of change in [11C]carfentanil and [11C]raclopride binding potential after a nonpharmacological challenge. Synapse, 2007, 61, 707-714.	1.2	59
123	BDNF Val66Met Allele Is Associated with Reduced Hippocampal Volume in Healthy Subjects. Biological Psychiatry, 2006, 59, 812-815.	1.3	412
124	Impact of Combined Estradiol and Norethindrone Therapy on Visuospatial Working Memory Assessed by Functional Magnetic Resonance Imaging. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 4476-4481.	3.6	61
125	Pronociceptive and Antinociceptive Effects of Estradiol through Endogenous Opioid Neurotransmission in Women. Journal of Neuroscience, 2006, 26, 5777-5785.	3.6	287
126	Variations in the Human Pain Stress Experience Mediated by Ventral and Dorsal Basal Ganglia Dopamine Activity. Journal of Neuroscience, 2006, 26, 10789-10795.	3.6	259

#	Article	IF	CITATIONS
127	Human brain mechanisms of pain perception and regulation in health and disease. European Journal of Pain, 2005, 9, 463-463.	2.8	2,538
128	Regional Cerebral Blood Flow Responses to Smoking in Tobacco Smokers After Overnight Abstinence. American Journal of Psychiatry, 2005, 162, 567-577.	7.2	112
129	Placebo Effects Mediated by Endogenous Opioid Activity on μ-Opioid Receptors. Journal of Neuroscience, 2005, 25, 7754-7762.	3.6	702
130	Neurobiological Mechanisms of the Placebo Effect. Journal of Neuroscience, 2005, 25, 10390-10402.	3.6	598
131	Face Emotion Perception and Executive Functioning Deficits in Depression. Journal of Clinical and Experimental Neuropsychology, 2005, 27, 320-333.	1.3	152
132	Interface of physical and emotional stress regulation through the endogenous opioid system and μ-opioid receptors. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2005, 29, 1264-1280.	4.8	132
133	HPA axis activation in major depression and response to fluoxetine: a pilot study. Psychoneuroendocrinology, 2004, 29, 1198-1204.	2.7	95
134	Priority actions to improve the care of persons with co-occurring substance abuse and other mental disorders: A call to action. Biological Psychiatry, 2004, 56, 703-713.	1.3	127
135	Regional cerebral blood flow and plasma nicotine after smoking tobacco cigarettes. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2004, 28, 319-327.	4.8	83
136	Changes in craving for a cigarette and arterial nicotine plasma concentrations in abstinent smokers. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2004, 28, 617-623.	4.8	19
137	Neuroreceptor Imaging of Stress and Mood Disorders. CNS Spectrums, 2004, 9, 292-301.	1.2	9
138	COMT <i> val ¹⁵⁸ met </i> Genotype Affects µ-Opioid Neurotransmitter Responses to a Pain Stressor. Science, 2003, 299, 1240-1243.	12.6	1,025
139	Effects of Buprenorphine Maintenance Dose on μ-Opioid Receptor Availability, Plasma Concentrations, and Antagonist Blockade in Heroin-Dependent Volunteers. Neuropsychopharmacology, 2003, 28, 2000-2009.	5.4	264
140	μ-Opioid Receptor-Mediated Antinociceptive Responses Differ in Men and Women. Journal of Neuroscience, 2002, 22, 5100-5107.	3.6	344
141	Vesicular monoamine transporter concentrations in bipolar disorder type I, schizophrenia, and healthy subjects. Biological Psychiatry, 2001, 49, 110-116.	1.3	88
142	Regional cerebral blood flow effects of nicotine in overnight abstinent smokers. Biological Psychiatry, 2001, 49, 906-913.	1.3	83
143	Neuroimaging of aging and estrogen effects on central nervous system physiology. Fertility and Sterility, 2001, 76, 651-659.	1.0	27
144	Long-term estrogen replacement is associated with improved nonverbal memory and attentional measures in postmenopausal women. Fertility and Sterility, 2001, 76, 1101-1107.	1.0	73

Jon-Kar Zubieta

#	Article	IF	CITATIONS
145	Cognitive function in euthymic Bipolar I Disorder. Psychiatry Research, 2001, 102, 9-20.	3.3	309
146	Assessment of muscarinic receptor concentrations in aging and Alzheimer disease with [11C]NMPB and PET. Synapse, 2001, 39, 275-287.	1.2	69
147	Nicotine effects on regional cerebral blood flow in awake, resting tobacco smokers. Synapse, 2000, 38, 313-321.	1.2	98
148	Buprenorphine-Induced Changes in Mu-Opioid Receptor Availability in Male Heroin-Dependent Volunteers A Preliminary Study. Neuropsychopharmacology, 2000, 23, 326-334.	5.4	116
149	In Vivo Measurement of the Vesicular Monoamine Transporter in Schizophrenia. Neuropsychopharmacology, 2000, 23, 667-675.	5.4	52
150	High Vesicular Monoamine Transporter Binding in Asymptomatic Bipolar I Disorder: Sex Differences and Cognitive Correlates. American Journal of Psychiatry, 2000, 157, 1619-1628.	7.2	102
151	Quantification of δ-Opioid Receptors in Human Brain with N1′ -([11C]Methyl) Naltrindole and Positron Emission Tomography. Journal of Cerebral Blood Flow and Metabolism, 1999, 19, 956-966.	4.3	46
152	Medial frontal cortex involvement in PTSD symptoms: a spect study. Journal of Psychiatric Research, 1999, 33, 259-264.	3.1	138
153	Gender and Age Influences on Human Brain Mu-Opioid Receptor Binding Measured by PET. American Journal of Psychiatry, 1999, 156, 842-848.	7.2	311
154	Quantification of Muscarinic Cholinergic Receptors with [11C]NMPB and Positron Emission Tomography: Method Development and Differentiation of Tracer Delivery from Receptor Binding. Journal of Cerebral Blood Flow and Metabolism, 1998, 18, 619-631.	4.3	39
155	Increased mu opioid receptor binding detected by PET in cocaine–dependent men is associated with cocaine craving. Nature Medicine, 1996, 2, 1225-1229.	30.7	250